Healthcare Portfolio Moves
Eversept Partners Shifts Healthcare Investments, Adding to Palisade Bio and HealthEquity While Trimming HCA
Key Points
In Assembly Biosciences (ASMB), Eversept’s new stake came alongside evidence of broader institutional activity: the article notes that 19.92% of ASMB is owned by institutional investors, and lists other investors that boosted positions (e.g., Vanguard Group up 97.8% to 502,112 shares; Acadian Asset Management up 42.1% to 23,027 shares).
For HCA Healthcare (HCA), Eversept’s cut was framed with additional portfolio context—HCA “makes up 2.3% of Eversept Partners LP’s portfolio” and is its “10th biggest position.” The article also reports analyst action, including Barclays cutting its HCA target price from $551 to $496 while keeping an “overweight” rating.
In HealthEquity (HQY), the article adds balance-sheet and market metrics: it states Eversept held HQY as its “28th biggest position” (about 0.9% of holdings) and provides company stats such as a 0.46 debt-to-equity ratio, quick/current ratio of 3.44, market cap of $7.22 billion, and beta of 0.21 (along with 50/200-day moving averages near $84.8/$85.35).
For Palisade Bio (PALI), the article specifies institutional ownership at 11.79% and provides more granular sell/hold/buy signals from analysts, including: Wall Street Zen raising PALI “from a ‘sell’ rating to a ‘hold’ rating,” HC Wainwright initiating coverage with a “buy” and a $7.00 target, Stifel Nicolaus issuing a “buy” with a $5.00 target, and Wolfe Research rating “outperform” with a $7.00 target.
For Beta Bionics (BBNX), beyond “negative P/E,” the article gives detailed trading and valuation indicators: it reports a market cap of $587.75 million, a P/E ratio of -8.74, beta of 3.40, and moving averages of $11.55 (50-day) and $16.23 (200-day), plus a 52-week range of $8.80 to $32.71.
Eversept Partners LP, a roughly $1.9 billion healthcare-focused hedge fund, disclosed a new $12.7 million stake in Palisade Bio, acquiring about 5.39 million shares of the small-cap biotech, according to MarketBeat. The firm made the bet shortly after Palisade reported a clean safety profile in a Phase 1b Crohn's Disease trial in March 2026, giving Eversept a clinical hook for entering the stock.
The Palisade move was just one piece of a broad portfolio reshuffle. Eversept also cut its HCA Healthcare stake by 14.2%, poured $17 million into HealthEquity, and opened a $20.7 million position in Beta Bionics — all revealed when Q1 13F filings became public on May 15, per SEC EDGAR.
Palisade Bio Draws Bullish Bets After Crohn's Data
Eversept now holds a sizable slice of Palisade Bio's 11.79% institutional ownership. The clinical catalyst was a Phase 1b study in Fibrostenotic Crohn's Disease that Palisade released on March 31, 2026. Researchers reported no serious safety concerns from the company's PALI-2108 prodrug, per Investing.com. That data appears to have cleared the bar Eversept needed before committing capital.
Analyst views on Palisade are sharply split. HC Wainwright initiated coverage with a "Buy" and a $7.00 target. Stifel also rated it "Buy" but set a more cautious $5.00 target. Wolfe Research called it "Outperform" with a $7.00 target. Meanwhile, Wall Street Zen upgraded the stock from "Sell" to "Hold," per Fintel. The wide range of targets — from $5 to $25 — shows the market is still waiting on Phase 2 ulcerative colitis data expected in late 2027.
Eversept Trims HCA as Hospital Margins Come Under Pressure
Eversept cut its HCA Healthcare position by 14.2%, leaving it with 95,874 shares worth about $44.8 million. HCA still makes up roughly 2.3% of Eversept's total portfolio and remains its 10th-largest holding. The trim came after HCA reported Q1 2026 earnings that missed per-share estimates — $7.15 actual versus $7.19 expected — despite hitting $19.11 billion in revenue, per MarketBeat.
Barclays analyst Andrew Mok kept an "Overweight" rating on HCA but cut his price target from $551 to $496, citing a "guidance reset" driven by high operating costs and weather-related disruptions, according to TipRanks. Interestingly, Barclays as an institution actually boosted its own HCA stake by 5.8% in the same period — a direct contradiction of what Eversept chose to do.
HealthEquity Stake More Than Triples as HSA Play Grows
Eversept's most aggressive move was in HealthEquity, where it boosted its position by 254.5% to 185,739 shares worth around $17.0 million. The stock now ranks as Eversept's 28th-largest holding at about 0.9% of total assets. HealthEquity operates health savings accounts, or HSAs — tax-advantaged accounts workers use to pay medical costs. Analysts project the company's revenue will reach $1.41 billion in fiscal 2027, per Seeking Alpha.
HealthEquity carries a conservative financial profile that may have attracted Eversept. Its debt-to-equity ratio sits at just 0.46. Its quick and current ratios both stand at 3.44, signaling strong short-term liquidity. The company's beta of 0.21 means its stock barely moves with the broader market — a stabilizing anchor in a portfolio that also includes high-volatility names.
Beta Bionics Bet Carries High Risk Amid Legal Scrutiny
Eversept opened a $20.7 million position in Beta Bionics, buying 678,262 shares of the medical device maker. Beta Bionics went public in January 2025 and sells the iLet Bionic Pancreas, a device that automates insulin delivery for diabetics. But the stock has been volatile. Its 52-week range runs from $8.80 to $32.71, and its 200-day moving average of $16.23 sits well above its current 50-day average of $11.55, per Morningstar.
The company carries a negative P/E of -8.74 and a market cap of $587.75 million. Its beta of 3.40 means it swings more than three times as much as the broader market. Adding to the pressure, law firms Robbins LLP and Faruqi & Faruqi announced shareholder investigations in June 2026 over concerns about slowing new patient growth for the iLet device, according to Business Wire. Eversept's entry at this moment makes the bet look like a high-conviction call on a recovery.
Sentiment
Mostly NegativePublishers
27
Articles
13
Reach
40
